Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$2.11 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 52.8% to -$2.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.04 through Dec 2025, down 108.04% year-over-year, with the annual reading at -$9.04 for FY2025, 108.03% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$2.11 at Inhibrx Biosciences, up from -$2.28 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $125.48 in Q2 2024, with the low at -$7.29 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is $7.94, with a median of -$2.84 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 3011.37% in 2024, then crashed 101.47% in 2025.
  • Over 3 years, EPS (Weighted Average and Diluted) stood at -$7.29 in 2023, then surged by 38.68% to -$4.47 in 2024, then surged by 52.8% to -$2.11 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$2.11, -$2.28, and -$1.85 for Q4 2025, Q3 2025, and Q2 2025 respectively.